Aroa Biosurgery Ltd

AU:ARX Australia Medical Devices
Market Cap
$124.54 Million
AU$201.14 Million AUD
Market Cap Rank
#18572 Global
#295 in Australia
Share Price
AU$0.58
Change (1 day)
-3.73%
52-Week Range
AU$0.38 - AU$0.80
All Time High
AU$1.54
Categories
Companies in Australia Medical Devices
About

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more

Aroa Biosurgery Ltd (ARX) - Net Assets

Latest net assets as of September 2025: AU$80.93 Million AUD

Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) has net assets worth AU$80.93 Million AUD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$95.27 Million) and total liabilities (AU$14.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$80.93 Million
% of Total Assets 84.95%
Annual Growth Rate 17.38%
5-Year Change 57.55%
10-Year Change 1330.9%
Growth Volatility 176.24

Aroa Biosurgery Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Aroa Biosurgery Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Aroa Biosurgery Ltd (2001–2025)

The table below shows the annual net assets of Aroa Biosurgery Ltd from 2001 to 2025.

Year Net Assets Change
2025-03-31 AU$84.59 Million -2.87%
2024-03-31 AU$87.09 Million -8.69%
2023-03-31 AU$95.38 Million +2.11%
2022-03-31 AU$93.40 Million +73.96%
2021-03-31 AU$53.69 Million -14.58%
2020-03-31 AU$62.86 Million +445.60%
2019-03-31 AU$11.52 Million +551.60%
2018-03-31 AU$1.77 Million -71.85%
2017-03-31 AU$6.28 Million +6.24%
2016-03-31 AU$5.91 Million -14.62%
2015-03-31 AU$6.92 Million -8.64%
2014-03-31 AU$7.58 Million -15.81%
2013-03-31 AU$9.00 Million -3.62%
2012-03-31 AU$9.34 Million +96.38%
2011-03-31 AU$4.76 Million +183.60%
2010-03-31 AU$1.68 Million +107.40%
2009-03-31 AU$-22.65 Million -25.01%
2008-03-31 AU$-18.12 Million -159.78%
2007-03-31 AU$30.31 Million -6.92%
2006-03-31 AU$32.56 Million +113.82%
2005-03-31 AU$15.23 Million +18.43%
2004-03-31 AU$12.86 Million +31.58%
2003-03-31 AU$9.77 Million -3.85%
2002-03-31 AU$10.16 Million +462.06%
2001-03-31 AU$1.81 Million --

Equity Component Analysis

This analysis shows how different components contribute to Aroa Biosurgery Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 5821337600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Common Stock AU$133.44 Million 157.75%
Other Comprehensive Income AU$9.36 Million 11.07%
Total Equity AU$84.59 Million 100.00%

Aroa Biosurgery Ltd Competitors by Market Cap

The table below lists competitors of Aroa Biosurgery Ltd ranked by their market capitalization.

Company Market Cap
Fonar Corporation
NASDAQ:FONR
 		$92.74 Million
Paiho Shih Holdings Corp
TW:8404
 		$92.78 Million
Fiera Milano S.p.A.
LSE:0EGH
 		$92.87 Million
Singatron Enterprise Co Ltd
TWO:6126
 		$92.90 Million
Lagenda Properties Bhd
KLSE:7179
 		$92.73 Million
CAMBI ASA NK -02
F:3W7
 		$92.70 Million
Korea Alcohol Industrial Co. Ltd
KQ:017890
 		$92.69 Million
Hung -Gu Oil Ltd
KQ:024060
 		$92.66 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aroa Biosurgery Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 87,079,495 to 84,591,966, a change of -2,487,529 (-2.9%).
  • Net loss of 3,465,103 reduced equity.
  • Share repurchases of 1,347,691 reduced equity.
  • New share issuances of 9,088 increased equity.
  • Other comprehensive income decreased equity by 80,194.
  • Other factors increased equity by 2,396,371.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-3.47 Million -4.1%
Share Repurchases AU$1.35 Million -1.59%
Share Issuances AU$9.09K +0.01%
Other Comprehensive Income AU$-80.19K -0.09%
Other Changes AU$2.40 Million +2.83%
Total Change AU$- -2.86%

Book Value vs Market Value Analysis

This analysis compares Aroa Biosurgery Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.36x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 98.43x to 2.36x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-03-31 AU$0.01 AU$0.58 x
2019-03-31 AU$0.04 AU$0.58 x
2020-03-31 AU$0.21 AU$0.58 x
2021-03-31 AU$0.18 AU$0.58 x
2022-03-31 AU$0.27 AU$0.58 x
2023-03-31 AU$0.28 AU$0.58 x
2024-03-31 AU$0.25 AU$0.58 x
2025-03-31 AU$0.25 AU$0.58 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aroa Biosurgery Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -4.10%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -4.50%
  • • Asset Turnover: 0.78x
  • • Equity Multiplier: 1.17x
  • Recent ROE (-4.10%) is above the historical average (-8.08%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 95.83% 0.00% 0.00x 3.06x AU$1.44 Million
2014 -19.34% -167.45% 0.10x 1.11x AU$-2.22 Million
2015 -23.34% -206.13% 0.10x 1.08x AU$-2.31 Million
2016 -21.87% -189.93% 0.11x 1.08x AU$-1.88 Million
2017 -11.51% 0.00% 0.00x 1.04x AU$-1.35 Million
2018 -66.67% -12.20% 0.68x 8.09x AU$-1.36 Million
2019 7.78% 4.12% 0.57x 3.29x AU$-255.85K
2020 -9.01% -23.76% 0.29x 1.31x AU$-11.95 Million
2021 -32.84% -85.98% 0.28x 1.36x AU$-23.00 Million
2022 -8.35% -21.13% 0.35x 1.12x AU$-17.13 Million
2023 -0.39% -0.62% 0.54x 1.14x AU$-9.91 Million
2024 -11.19% -15.39% 0.62x 1.17x AU$-18.46 Million
2025 -4.10% -4.50% 0.78x 1.17x AU$-11.92 Million

Industry Comparison

This section compares Aroa Biosurgery Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $18,906,316
  • Average return on equity (ROE) among peers: -350.21%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Aroa Biosurgery Ltd (ARX) AU$80.93 Million 95.83% 0.18x $92.74 Million
4DMEDICAL Ltd (4DX) $926.64K -85.93% 0.18x $1.03 Billion
Adherium Ltd (ADR) $34.53 Million -3.63% 0.08x $2.37 Million
Atomo Diagnostics Ltd (AT1) $34.48 Million -26.73% 0.05x $8.96 Million
Control Bionics Ltd (CBL) $6.09 Million -15.97% 0.04x $4.98 Million
Cardiex Ltd (CDX) $3.03 Million -101.61% 0.73x $4.25 Million
Compumedics Ltd (CMP) $9.21 Million -30.70% 1.16x $13.08 Million
Cochlear Ltd (COH) $75.42 Million 53.19% 1.13x $7.01 Billion
Cleo Diagnostics Ltd (COV) $5.83 Million -68.54% 0.19x $23.47 Million
Conneqt Health Limited (CQT) $633.50K -2871.98% 13.72x $4.66 Million